Testing tarlatamab before and after surgery for high-grade glioma that came back
Original title: Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called tarlatamab in people having surgery for a brain tumor that came back.
Who this trial is for. This trial is for adults whose high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has come back and who can have surgery. Their tumor must test positive for a marker called DLL3, and their surgery must be safe to delay. They get tarlatamab through a vein before surgery, then start it again after they recover.
Where it stands. This trial has not reported results. It is looking at whether tarlatamab is safe to give before surgery. It also counts how many people can finish that first part and still have their planned surgery. After surgery, people keep getting the drug every 2 weeks for up to 6 cycles, and side effects are tracked. The answers are not in yet.
What this means, and what it doesn't
What it could mean: No one knows yet if this drug helps people with this tumor. Someone who fits this trial could ask their care team about it. The trial team decides who can take part.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, August 26, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.